Central Health

centralhealth.nl.ca

Central Health is the second largest health region in Newfoundland and Labrador, providing health and community services to approximately 20 per cent of the province’s population. Our 94,000 clients, patients, residents, and their families live in 177 communities in a region that extends from Charlottetown in the east, Fogo Island in the north, Harbour Breton in the south, to Baie Verte in the west.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Medical

BE BIO AND RESILIENCE ANNOUNCE STRATEGIC COLLABORATION TO MANUFACTURE ENGINEERED B CELLS, A NEW CLASS OF CELLULAR MEDICINES

Be Bio | May 20, 2022

news image

Be Biopharma, Inc. (“Be Bio”) and National Resilience, Inc. (Resilience) today announced a strategic collaboration to advance initial programs in Be Bio’s rare disease pipeline. Be Bio’s proprietary engineered B Cell Medicines (BeCM) platform is harnessing the power of the human B cell to create a new class of autologous and allogeneic cellular medicines that durably and redosably produce therapeutic proteins in vivo without toxic pre-conditioning. The two ...

Read More

MedTech

CELLCARTA EXPANDS ITS BIOMARKER CAPABILITIES FOR CLINICAL TRIALS BY ADDING OLINK TECHNOLOGY TO ITS GLOBAL SERVICES

CellCarta | September 01, 2021

news image

CellCarta and Olink Proteomics AB announced today a strategic collaboration to offer Olink® Target 96 & Target 48 to pharmaceutical and biotech customers, advancing targeted protein biomarker quantification in clinical studies. CellCarta is a global leader in precision medicine and with more than 20 years of experience in mass spectrometry the company continues to invest in the field of proteomic biomarkers to better understand diseases and support therapeutic development ...

Read More

XYLYX BIO RELEASES NORMAL AND FIBROTIC NATIVECOAT™ ECM SUBSTRATES INCREASE PREDICTIVENESS OF HIGH THROUGHPUT COMPOUND SCREENING

Xylyx Bio | August 27, 2020

news image

New York-based Xylyx Bio, a leader in advanced disease models, today announced the release of normal and fibrotic NativeCoat™ human lung- and liver-specific ECM substrates for antifibrotic drug discovery to increase predictiveness of high throughput screening and improve evaluation of efficacy of biopharmaceutical drug candidates for hard to treat fibrotic diseases such as IPF and NASH. Despite billions of dollars spent each year, 9 out of 10 drugs fail to make it to market, in part due to...

Read More

Cell and Gene Therapy, Industrial Impact

IMMUNOGEN ANNOUNCES MULTI-TARGET LICENSING AND OPTION DEAL WITH VERTEX

ImmunoGen, Inc. | March 02, 2023

news image

On March 1, 2023, ImmunoGen, Inc., a leading firm specializing in antibody-drug conjugates (ADCs), announced a global, multi-target license and option agreement with Vertex Pharmaceuticals. The deal provides Vertex with the rights to use ImmunoGen's ADC technology to research and discover targeted conditioning agents to be used in gene editing. After each research period, Vertex will have the option to obtain an exclusive worldwide license to research, develop, and commercia...

Read More
news image

Medical

BE BIO AND RESILIENCE ANNOUNCE STRATEGIC COLLABORATION TO MANUFACTURE ENGINEERED B CELLS, A NEW CLASS OF CELLULAR MEDICINES

Be Bio | May 20, 2022

Be Biopharma, Inc. (“Be Bio”) and National Resilience, Inc. (Resilience) today announced a strategic collaboration to advance initial programs in Be Bio’s rare disease pipeline. Be Bio’s proprietary engineered B Cell Medicines (BeCM) platform is harnessing the power of the human B cell to create a new class of autologous and allogeneic cellular medicines that durably and redosably produce therapeutic proteins in vivo without toxic pre-conditioning. The two ...

Read More
news image

MedTech

CELLCARTA EXPANDS ITS BIOMARKER CAPABILITIES FOR CLINICAL TRIALS BY ADDING OLINK TECHNOLOGY TO ITS GLOBAL SERVICES

CellCarta | September 01, 2021

CellCarta and Olink Proteomics AB announced today a strategic collaboration to offer Olink® Target 96 & Target 48 to pharmaceutical and biotech customers, advancing targeted protein biomarker quantification in clinical studies. CellCarta is a global leader in precision medicine and with more than 20 years of experience in mass spectrometry the company continues to invest in the field of proteomic biomarkers to better understand diseases and support therapeutic development ...

Read More
news image

XYLYX BIO RELEASES NORMAL AND FIBROTIC NATIVECOAT™ ECM SUBSTRATES INCREASE PREDICTIVENESS OF HIGH THROUGHPUT COMPOUND SCREENING

Xylyx Bio | August 27, 2020

New York-based Xylyx Bio, a leader in advanced disease models, today announced the release of normal and fibrotic NativeCoat™ human lung- and liver-specific ECM substrates for antifibrotic drug discovery to increase predictiveness of high throughput screening and improve evaluation of efficacy of biopharmaceutical drug candidates for hard to treat fibrotic diseases such as IPF and NASH. Despite billions of dollars spent each year, 9 out of 10 drugs fail to make it to market, in part due to...

Read More
news image

Cell and Gene Therapy, Industrial Impact

IMMUNOGEN ANNOUNCES MULTI-TARGET LICENSING AND OPTION DEAL WITH VERTEX

ImmunoGen, Inc. | March 02, 2023

On March 1, 2023, ImmunoGen, Inc., a leading firm specializing in antibody-drug conjugates (ADCs), announced a global, multi-target license and option agreement with Vertex Pharmaceuticals. The deal provides Vertex with the rights to use ImmunoGen's ADC technology to research and discover targeted conditioning agents to be used in gene editing. After each research period, Vertex will have the option to obtain an exclusive worldwide license to research, develop, and commercia...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us